The 40 Percent Valuation Haircut
The Sovereign Discount and the End of Predictable Exclusivity The traditional pharmaceutical valuation model, long built on the bedrock of […]
The 40 Percent Valuation Haircut Read Post »
The 505(b)(2) Playbook: Scale Your Pipeline Without the Billion-Dollar Gamble
The pharmaceutical industry is currently trapped in a pincer movement. On one side, the cost of developing a new molecular
The 505(b)(2) Playbook: Scale Your Pipeline Without the Billion-Dollar Gamble Read Post »
The Evergreening Gambit: A Strategic Guide to Pharmaceutical Patent Lifecycle Management
In pharmaceutical development the term “evergreening” is a lightning rod. To its critics—consumer advocates, public health officials, and generic drug
The Evergreening Gambit: A Strategic Guide to Pharmaceutical Patent Lifecycle Management Read Post »
How to Re-Patent a Generic Drug
The economic reality of contemporary drug discovery suggests that the traditional model of pharmaceutical research is becoming an exercise in
How to Re-Patent a Generic Drug Read Post »
The Global Chessboard: Decoding Drug Patent Linkage for Competitive Dominance in Pharma
In pharmaceuticals market exclusivity is the ultimate prize. It is the golden period during which an innovator company can recoup
The Global Chessboard: Decoding Drug Patent Linkage for Competitive Dominance in Pharma Read Post »
How To Turn Known Molecules Into Proprietary Assets
The Capital Efficiency of Repurposed Innovation Pharmaceutical companies face a brutal economic reality. Developing a new chemical entity now requires
How To Turn Known Molecules Into Proprietary Assets Read Post »
Trust is the new patent: How to charge 40% more for the same pill
The pharmaceutical industry operates on a punishing mathematical reality. In 2024, generic and biosimilar medicines accounted for 90% of all
Trust is the new patent: How to charge 40% more for the same pill Read Post »
The Trust Proxy: How To Capture The 40% Emerging Market Revenue Shift
Money is moving. The global pharmaceutical industry is currently witnessing a structural relocation of profit that will redefine the balance
The Trust Proxy: How To Capture The 40% Emerging Market Revenue Shift Read Post »
The Data-Driven Guide to Winning the 2026 Patent Cliff
The Pricing Shock: How the Inflation Reduction Act Rewrites the Valuation Rules The economic foundations of the pharmaceutical industry are
The Data-Driven Guide to Winning the 2026 Patent Cliff Read Post »
